Navigation Links
BioMarin to Present at the William Blair Growth Stock Conference

NOVATO, Calif., June 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the William Blair Growth Stock Conference in Chicago on Wednesday, June 15, 2011 at 10:00 a.m. CT.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website,  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the Jefferies Global Healthcare Conference
2. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
3. BioMarin Announces First Quarter 2011 Financial Results
4. BioMarin to Present at the Deutsche Bank Healthcare Conference
5. BioMarin to Present at the Barclays Global Healthcare Conference
6. BioMarin to Present at the Cowen Health Care Conference
7. BioMarin to Present at the Citi Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
9. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
10. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
11. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Post Your Comments:
(Date:10/13/2015)... VIVA Physicians, a not-for-profit organization dedicated to ... education and research, is excited to announce the late-breaking ... trial results, featuring the latest in vascular technology and ... Monday and Tuesday, November 2 and 3 at the ... --> Since 2003, VIVA Physicians has sponsored this ...
(Date:10/13/2015)... BROOMFIELD, Colo. , Oct. 13, 2015  The ... a global leader in musculoskeletal healthcare, will showcase its ... North American Spine Society (NASS) annual meeting, October 14-17, ... Biomet will also host two clinical events: ... Hall Floor Presentation Wednesday, October 14 12:30 – 1 ...
(Date:10/13/2015)... PITTSBURGH , Oct. 13, 2015  Data Science Automation ... the opening of a new branch office in the ... of DSA,s presence in Europe . The ... the increasing demand for local support of customers in the ... , Ph.D., DSA,s UK Branch Manager. "We have had tremendous ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... The documentary Pink & Blue: Colors ... Beverly Hills October 2 - 8, coinciding with National Hereditary Breast & Ovarian Cancer ... takes us through the lives of women - and men - who are dealing ...
(Date:10/13/2015)... ... 13, 2015 , ... The added calories and sugar in an average trick-or-treat ... a parent to do? Registered dietitians from Retrofit , the leading corporate weight ... year. , “Halloween is a high-calorie holiday,” said Dara Aronow, Registered Dietitian, Retrofit. ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... new Pillars of Excellence in the Life Sciences Initiative aimed at enhancing Purdue’s ... recently announced $2 billion “Ever True” capital campaign. , The investment will result ...
(Date:10/13/2015)... Palm Beach, FL (PRWEB) , ... October 13, 2015 , ... ... of Global Laser Vision of San Diego, California. With brands including The LASIK Vision ... million successful procedures, making it the nationwide leader in laser vision correction. , Global ...
(Date:10/13/2015)... ... October 13, 2015 , ... CURE Media Group, the ... a new partnership with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) to ... their families and physicians. , “Waldenstrom’s Macroglobulinemia is a so-called ‘orphan disease’ ...
Breaking Medicine News(10 mins):